Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-062 phase 2 dose-ranging study in active celiac disease
2020-005438-14Phase 2Completed
- Sponsor
- Takeda
- Start
- Jul 2022
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of zamaglutenase in celiac disease (4 arms), sponsored by Takeda. Primary endpoint: Change in CDSD GI symptom severity score. Started Jul 2022; status: completed.
02
Drugs
zamaglutenase
03
Conditions
celiac disease
Beyond the preview
Go deeper on 2020-005438-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005438-14.